# Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

> **NCT01625338** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 534 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** SOF
- **DRUG:** RBV
- **DRUG:** Peg-IFN

## Key facts

- **NCT ID:** NCT01625338
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 534 (ACTUAL)
- **Last updated:** 2015-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01625338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01625338, "Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01625338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*